Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSZQHX)

Drug Name

BI-505 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 2	[1]

Cross-matching ID

TTD Drug ID: DMSZQHX

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Intercellular adhesion molecule ICAM-1 (ICAM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
lifitegrast	DM4WVC5	Dry eye disease	9E1Z	Approved	[3]
Alicaforsen	DMQ509J	Lleum inflammation	1A40.0	Phase 3	[4]
APC-8015F	DM3VP19	Prostate cancer	2C82.0	Phase 2	[5]
AIC100	DMSPBOW	Thyroid cancer	2D10	Phase 1	[6]
GI-270384X	DM3KN2Q	Inflammatory bowel disease	DD72	Terminated	[7]
A-252444.0	DMDTA36	Inflammation	1A00-CA43.1	Terminated	[8]
MOR-102	DMRCH1M	Psoriasis vulgaris	EA90	Terminated	[9]
ISIS-1939	DMGN4OQ	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Drug(s) Targeting Tyrosine-protein kinase UFO (AXL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gilteritinib	DMTI0ZO	Acute myeloid leukaemia	2A60	Approved	[11]
MGCD265	DMRPCF2	Non-small-cell lung cancer	2C25.Y	Phase 2	[12]
Bemcentinib	DM0YCPL	Myelodysplastic syndrome	2A37	Phase 2	[13]
BGB-324	DMDI43Y	Breast cancer	2C60-2C65	Phase 2	[14]
Mecbotamab vedotin	DMU5KH4	Ovarian cancer	2C73	Phase 2	[15]
ONO-7475	DMV6GX7	Acute leukaemia	2A60	Phase 1/2	[11]
ONO-7475	DMV6GX7	Acute leukaemia	2A60	Phase 1/2	[16]
TP-0903	DMHTG8P	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[11]
Enapotamab vedotin	DM1PQJO	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[17]
RXDX-106	DM6NVTR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Intercellular adhesion molecule ICAM-1 (ICAM1)	TTCT6F7	ICAM1_HUMAN	Not Available	[2]
Tyrosine-protein kinase UFO (AXL)	TTZPY6J	UFO_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15.
3	Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	National Cancer Institute Drug Dictionary (drug id 561410).
6	Clinical pipeline report, company report or official report of AffyImmune Therapeutics.
7	Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96.
8	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012566)
9	Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br J Dermatol. 2005 Oct;153(4):758-66.
10	Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem. 1991 Sep 25;266(27):18162-71.
11	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12	Company report (Mirati Therapeutics: formerly MethylGene)
13	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999.
14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835).
15	Clinical pipeline report, company report or official report of BioAtla
16	Clinical pipeline report, company report or official report of Ono Pharmaceutical.
17	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199.
18	National Cancer Institute Drug Dictionary (drug name RXDX106).